ENLVEnlivex Ltd.
Chart data are delayed by 15 minutes.
Main metrics
Providers
All 2 issuers →
Ondo FinanceENLVon$1.8K100.0%
RealityrENLV—0.0%Chains
All 4 chains →
BNB Chain$1.58K87.8%
Ethereum$134.467.5%
Solana$86.044.8%
Arbitrum One—0.0%About ENLV
Enlivex Ltd. is a clinical-stage biotechnology company focused on macrophage reprogramming immunotherapy and inflammatory disease treatment. Its lead program, Allocetra, is designed to restore immune balance by reprogramming macrophages, with development efforts centered on conditions such as sepsis and osteoarthritis. The company’s current pipeline includes cell-based therapies for immune-related disorders and degenerative joint disease, reflecting its emphasis on novel approaches to immune modulation. Enlivex Ltd. operates from Ness Ziona, Israel, and serves the healthcare and biopharmaceutical markets through research, clinical development, and therapeutic innovation. The company’s role in the market is to advance experimental treatments that address unmet medical needs in inflammation-driven and immune dysregulation conditions.
Valuation
Profitability
Balance sheet
Trading
| Issuer | Token | Chains | Dividend | Shares | Value | Share |
|---|---|---|---|---|---|---|
| Ondo Finance | ENLVonEnlivex Therapeutics (Ondo Tokenized) | | 1.6K | $1.8K | 100.0% | |
| Reality | rENLVEnlivex (Reality) | | 0 | — | 0.0% |
| Chain | Issuers | Shares | Value | Share |
|---|---|---|---|---|
| BNB Chain | | 1.4K | $1.58K | 87.8% |
| Ethereum | | 122.2 | $134.46 | 7.5% |
| Solana | | 78.2 | $86.04 | 4.8% |
| Arbitrum One | | 0 | — | 0.0% |
No dividend has been recorded for this asset.
| Date | Type | Details |
|---|---|---|
| Jul 9, 2026 | Reverse split | 1-for-1515 shares → 1 share |
| Mar 6, 2019 | Reverse split | 1-for-88 shares → 1 share |
| Sep 25, 2017 | Reverse split | 1-for-55 shares → 1 share |
Splits, mergers and other corporate actions appear here. How each issuer reflects them on-chain varies by product.
